RT Journal Article
SR Electronic
T1 Deciphering causal protein biomarkers in Alzheimer’s disease: Integrating a novel robust Mendelian randomization method for proteomics data analysis and AlphaFold3 for predicting 3D structural alterations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.20.23286200
DO 10.1101/2023.02.20.23286200
A1 Yao, Minhao
A1 Miller, Gary W.
A1 Vardarajan, Badri N.
A1 Baccarelli, Andrea A.
A1 Guo, Zijian
A1 Liu, Zhonghua
YR 2024
UL http://medrxiv.org/content/early/2024/10/02/2023.02.20.23286200.abstract
AB Hidden confounding bias is a major threat in identifying causal protein biomarkers for Alzheimer’s disease in non-randomized studies. Mendelian randomization (MR) framework holds the promise of removing such hidden confounding bias by leveraging protein quantitative trait loci (pQTLs) as instrumental variables (IVs) for establishing causal relationships. However, some pQTLs might violate core IV assumptions, leading to biased causal inference and misleading scientific conclusions. To address this urgent challenge, we propose a novel MR method called MR-SPI that first Selects valid pQTL IVs under the Anna Karenina Principle and then performs valid Post-selection Inference that is robust to possible pQTL selection error. We further develop a computationally efficient pipeline by integrating MR-SPI and AlphaFold3 to automatically identify causal protein biomarkers and predict protein 3D structural alterations. We apply this pipeline to analyze genome-wide summary statistics for 912 plasma proteins in 54,306 participants from UK Biobank and for Alzheimer’s disease (AD) in 455,258 samples. We identified seven proteins associated with Alzheimer’s disease - TREM2, PILRB, PILRA, EPHA1, CD33, RET, and CD55 - whose 3D structures are altered by missense genetic variations. Our findings offers novel insights into their biological roles in AD development and may aid in identifying potential drug targets.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used openly available human data that were originally located at: https://gwas.mrcieu.ac.uk/ http://www.cardiogramplusc4d.org/data-downloads/ https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files https://www.covid19hg.org/ I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.